Ventures

Rare diseases often lead to years of diagnostic odyssey and immense patient suffering. Therefore Genorare is set to dramatically shorten this diagnostic journey for individuals with rare diseases. Genorare's platform enables real-time, secure analysis of genomic, clinical, and phenotypic data using Large Language Models, predictive analytics, and Fully Homomorphic Encryption. A key innovation is the use of Fully Homomorphic Encryption, a next-generation privacy technology that allows for advanced analysis while ensuring patient data remains completely secure, promising a new standard of care for the rare disease community.

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

The rising number of surgeries in healthcare systems like the National Health Service is challenging due to increasing demand and backlogs. However, new solutions like the Asclepius Platform aim to streamline assessments before and after surgery using digital tools and AI. By analyzing patient data, it helps doctors make better decisions, reduce complications, and improve patient outcomes. Designed with input from patients, it's a cost-effective way to make surgery safer and more efficient.

MLA Diagnostics improves melanoma diagnosis, offering personalized measurement of malignancy levels. Traditional diagnosis often leads to overtreatment or undertreatment, resulting in patient distress or undetected cancer progression. By analyzing methylation, our test provides accurate prognosis, enabling tailored treatment plans and saving lives. With the melanoma therapeutics market on the rise, our innovative solution is poised to make a significant impact, improve patient outcomes and create opportunities.

Persuasive addresses the challenge of identifying Stable Angina patients early on, crucial for preventing heart attacks. Currently, without a diagnostic test in general practitioner settings, many referrals to hospitals prove unnecessary. The solution is a simple blood test, leveraging an extracellular vesicle protein signature to distinguish SA patients from those with non-cardiac chest pain. This innovative approach promises to streamline patient management, saving lives and healthcare resources.

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

Exolvo Biosciences, a collaboration between NLC Health Ventures and Verily (Google) Life Sciences, is revolutionizing oral drug delivery for large molecules like biologics. Our smart capsule technology, originating from the Google X moonshot program, eliminates painful injections and maximizes medication effectiveness. With ongoing pre-clinical testing and plans for an IND package in the U.S., we're poised to redefine drug delivery standards.